tbuckley/cabot-search huggingface dataset:
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i>-Mutated HER2-Positive Metastatic Breast Cancer
Authors: Komal Jhaveri, Joshua Z. Drago, Payal Deepak Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal Rosen, Monica N. Fornier, Nancy T. Sklarin, Sarat Chandarlapaty, Shanu Modi
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer; however, inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3, and PI3K overcomes this mechanism preclinically. Patients and Methods: This phase I study investigated the MTD of alpelisib given in combination with trastuzumab and LJM716 (a HER3-targeted antibody) in patients with PIK3CA-mutant HER2-positive (HER2+) metastatic breast cancer (MBC) using the continual reassessment method. Secondary analyses included efficacy and exploratory correlative studies. Results: Ten patients were treated initially with daily alpelisib (arm A). Grade ≥3 adverse events seen in ≥2 patients included diarrhea (n = 6), hypokalemia (n = 3), abnormal liver enzymes (n = 3), hyperglycemia (n = 2), mucositis (n = 2), and elevated lipase (n = 2). The MTD of alpelisib in arm A was 250 mg daily. This prompted the opening of arm B in which 11 patients received intermittently dosed alpelisib. Grade ≥3 adverse events seen in ≥2 patients included diarrhea (n = 5), hypokalemia (n = 3), and hypomagnesemia (n = 2). The MTD of alpelisib in arm B was 350 mg given 4 days on, 3 days off. Among 17 patients assessed, 1 had a partial response, 14 had stable disease, and 2 had disease progression at best response. Five patients had stable disease for &amp;gt;30 weeks. mRNA profiling of pre- and on-treatment tissue demonstrated PIK3CA target engagement by alpelisib via induction of downstream signaling and feedback pathways. Conclusions: Combination treatment with alpelisib, trastuzumab, and LJM716 was limited by gastrointestinal toxicity. Further efforts are warranted to target the PI3K pathway in HER2+ MBC.
Abstract 14421: Hax1 Inhibits Mst1 to Promote Pro-angiogeneic Effects of Cardiac Stem Cells for Myocardial Repair
Authors: Wen-Feng Cai, Lei Wang, Lin Jiang, Paul Christian, Meifeng Xu, Ronald W Millard, Yigang Wang
Journal: Circulation (2016)

Background: Our previous study revealed that HCLS-associated protein X-1 (HAX1) could regulate Hippo cascades to enhance the therapeutic effects of sca1+ cardiac stem cells (CSCssca1+) in a mouse m...
COVID-19 ASSOCIATED DECREMENTS IN LEFT VENTRICULAR FUNCTION PREDICT MORTALITY
Authors: Lakshmi Nambiar, Alexander Volodarskiy, Arielle Kushman, Romina Tafreshi, Hannah W. Mitlak, Privthi Mohan, Sophie Mou, Evelyn Horn, Parag Goyal, Monika Safford, Richard Devereux, Jonathan Weinsaft, Jiwon Kim
Journal: Journal of the American College of Cardiology (2021)
Covid-19: Students overlooked for vaccine in favour of family members at Dublin hospital
Authors: Clare Dyer
Journal: BMJ (2021)

A decision at the Coombe Women and Infants University Hospital in Dublin to give leftover covid-19 vaccine to family members of staff has sparked newspaper headlines, calls for the hospital's master to resign, and allegations that its board is trying to silence a critical consultant.Senior counsel Brian Kennedy, commissioned to establish the facts on the incident by the hospital board, was told that, on the evening of 8 January, the queue for vaccinations of frontline workers "thinned out quickly shortly after 8.30 pm, which was unanticipated." 1 Vials of Pfizer-BioNTech vaccine drawn up had to be used by 2.30 am or discarded, Kennedy was told.He reported that, after a "short and informal conversation" between 11 individuals, a consensus was reached that any leftover doses should be made available to family members of those present.1
RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells
Authors: Joydeep Mukherjee, Ajay Pandita, Chatla Kamalakar, Tor-Christian Johannessen, Shigeo Ohba, Yongjian Tang, Cecilia L. Dalle-Ore, Rolf Bjerkvig, Russell O. Pieper
Journal: Science Translational Medicine (2021)

Tumor cells using the ALT mechanism to maintain telomeres are uniquely sensitive to PARP inhibitor–induced lethal chromosomal fusion.
Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2)
Authors: Edward J Gane, Stephen Pianko, Stuart K Roberts, Alex J Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben Ari, Graham R Foster, Kosh Agarwal, Alex L Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Jerry J Li, Shuyan Wan, Frank Dutko, Bach-Yen T Nguyen, Janice Wahl, Eliav Barr, Joan R Butterton, Rafael Esteban
Journal: Hepatology (2015)
Research status of biodegradable metals designed for oral and maxillofacial applications: A review
Authors: Dandan Xia, Fan Yang, Yufeng Zheng, Yunsong Liu, Yongsheng Zhou
Journal: Bioactive Materials (2021)

The oral and maxillofacial regions have complex anatomical structures and different tissue types, which have vital health and aesthetic functions. Biodegradable metals (BMs) is a promising bioactive materials to treat oral and maxillofacial diseases. This review summarizes the research status and future research directions of BMs for oral and maxillofacial applications. Mg-based BMs and Zn-based BMs for bone fracture fixation systems, and guided bone regeneration (GBR) membranes, are discussed in detail. Zn-based BMs with a moderate degradation rate and superior mechanical properties for GBR membranes show great potential for clinical translation. Fe-based BMs have a relatively low degradation rate and insoluble degradation products, which greatly limit their application and clinical translation. Furthermore, we proposed potential future research directions for BMs in the oral and maxillofacial regions, including 3D printed BM bone scaffolds, surface modification for BMs GBR membranes, and BMs containing hydrogels for cartilage regeneration, soft tissue regeneration, and nerve regeneration. Taken together, the progress made in the development of BMs in oral and maxillofacial regions has laid a foundation for further clinical translation.
EFFECT OF DIFFERENT ANTHROPOMETRIC BODY INDICES ON RADIATION EXPOSURE IN PATIENTS UNDERGOING CARDIAC CATHETERISATION AND PERCUTANEOUS CORONARY INTERVENTION
Authors: Youlin Koh, Sara Vogrin, Samer Noaman, Simon Lam, Raymond Pham, Andrew Clark, Leah Biffin, Laura Hanson, Jason Bloom, Dion Stub, Angela Brennan, Christopher Reid, Diem T. Dinh, Jeffrey Lefkovits, Nicholas Cox, William Chan
Journal: Journal of the American College of Cardiology (2021)
A 7-YEAR WARRANTY PERIOD FOR CHEST PAIN PATIENTS WITH A NORMAL QUANTITATIVE [15O] H2O PET MYOCARDIAL PERFUSION SCAN
Authors: Ruurt Jukema, Pepijn Van Diemen, Roel Driessen, Wijnand Stuijfzand, Michiel Bom, Stefan Schumacher, Henk Everaars, Pieter Raijmakers, Ruben de Winter, Peter van de Ven, Albert van Rossum, Paul Knaapen, Ibrahim Danad
Journal: Journal of the American College of Cardiology (2021)
Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition
Authors: Qingqing Xiong, Yang Bai, Run Shi, Jian Wang, Weiguo Xu, Mingming Zhang, Tianqiang Song
Journal: Bioactive Materials (2021)

Chemotherapy, as one of the most commonly used treatment modalities for cancer therapy, provides limited benefits to hepatoma patients, owing to its inefficient delivery as well as the intrinsic chemo-resistance of hepatoma. Bioinformatic analysis identified the therapeutic role of a liver-specific microRNA — miR-122 for enhancing chemo-therapeutic efficacy in hepatoma. Herein, a cyclodextrin-cored star copolymer nanoparticle system (sCDP/DOX/miR-122) is constructed to co-deliver miR-122 with doxorubicin (DOX) for hepatoma therapy. In this nanosystem, miR-122 is condensed by the outer cationic poly (2-(dimethylamino) ethyl methacrylate) chains of sCDP while DOX is accommodated in the inner hydrophobic cyclodextrin cavities, endowing a sequential release manner of miR-122 and DOX. The preferentially released miR-122 not only directly induces cell apoptosis by down regulation of Bcl-w and enhanced p53 activity, but also increases DOX accumulation through inhibiting cytotoxic efflux transporter expression, which realizes synergistic performance on cell inhibition. Moreover, sCDP/DOX/miR-122 displays remarkably increased anti-tumor efficacy in vivo compared to free DOX and sCDP/DOX alone, indicating its great promising in hepatoma therapy.
FUNCTIONAL CORONARY ANGIOGRAPHY-DERIVED INDEX OF MICROCIRCULATORY RESISTANCE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Doosup Shin, Ki Hong Choi, Neng Dai, Seung Hun Lee, Juwon Kim, Hyun Sung Joh, Hyun Kuk Kim, Ki-Hyun Jeon, Sang Jin Ha, Sung Mok Kim, Mi Ja Jang, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo-Yong Hahn, Joon-Hyung Doh, Eun-Seok Shin, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo Myung Lee
Journal: Journal of the American College of Cardiology (2021)
COMPARISON OF IN-HOSPITAL OUTCOMES BETWEEN IMPLANTATION OF PERCUTANEOUS VENTRICULAR ASSIST DEVICES AND INTRA-AORTIC BALLOON PUMPS AMONG PATIENT WITH ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE
Authors: Abdulrahman Gamam, Trivian Nguyen, Fredrick Ogugua
Journal: Journal of the American College of Cardiology (2021)
Lies Before Retirement
Authors: Michael Salcman
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Suicide and self-harm in adult survivors of critical illness: population based cohort study
Authors: Shannon M Fernando, Danial Qureshi, Manish M Sood, Michael Pugliese, Robert Talarico, Daniel T Myran, Margaret S Herridge, Dale M Needham, Bram Rochwerg, Deborah J Cook, Hannah Wunsch, Robert A Fowler, Damon C Scales, O Joseph Bienvenu, Kathryn M Rowan, Magdalena Kisilewicz, Laura H Thompson, Peter Tanuseputro, Kwadwo Kyeremanteng
Journal: BMJ (2021)

Abstract Objective To analyse the association between survival from critical illness and suicide or self-harm after hospital discharge. Design Population based cohort study using linked and validated provincial databases. Setting Ontario, Canada between January 2009 and December 2017 (inclusive). Participants Consecutive adult intensive care unit (ICU) survivors (≥18 years) were included. Linked administrative databases were used to compare ICU hospital survivors with hospital survivors who never required ICU admission (non-ICU hospital survivors). Patients were categorised based on their index hospital admission (ICU or non-ICU) during the study period. Main outcome measures The primary outcome was the composite of death by suicide (as noted in provincial death records) and deliberate self-harm events after discharge. Each outcome was also assessed independently. Incidence of suicide was evaluated while accounting for competing risk of death from other causes. Analyses were conducted by using overlap propensity score weighted, cause specific Cox proportional hazard models. Results 423 060 consecutive ICU survivors (mean age 61.7 years, 39% women) were identified. During the study period, the crude incidence (per 100 000 person years) of suicide, self-harm, and the composite of suicide or self-harm among ICU survivors was 41.4, 327.9, and 361.0, respectively, compared with 16.8, 177.3, and 191.6 in non-ICU hospital survivors. Analysis using weighted models showed that ICU survivors ( v non-ICU hospital survivors) had a higher risk of suicide (adjusted hazards ratio 1.22, 95% confidence interval 1.11 to 1.33) and self-harm (1.15, 1.12 to 1.19). Among ICU survivors, several factors were associated with suicide or self-harm: previous depression or anxiety (5.69, 5.38 to 6.02), previous post-traumatic stress disorder (1.87, 1.64 to 2.13), invasive mechanical ventilation (1.45, 1.38 to 1.54), and renal replacement therapy (1.35, 1.17 to 1.56). Conclusions Survivors of critical illness have increased risk of suicide and self-harm, and these outcomes were associated with pre-existing psychiatric illness and receipt of invasive life support. Knowledge of these prognostic factors might allow for earlier intervention to potentially reduce this important public health problem.
DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
Authors: Yanli Bi, Xiaoyu Chen, Bajin Wei, Linchen Wang, Longyuan Gong, Haomin Li, Xiufang Xiong, Yongchao Zhao
Journal: Theranostics (2021)

Rationale: Dysregulation of the PI3K/AKT/mTOR pathway occurs frequently in cancers, providing an attractive therapeutic target for anticancer treatments. DEPTOR plays essential roles in regulation of cell proliferation and survival by directly modulating mTOR activity. However, whether DEPTOR regulates the growth of ErbB2-positive breast cancer cells remains unknown. Methods: DEPTOR expression was determined by TCGA data analysis and immunohistochemistry of human breast tissue microarrays. The membrane localization of DEPTOR was demonstrated by immunofluorescence and subcellular fractionation. The interaction of DEPTOR with ErbB2 was determined by immunoprecipitation. Furthermore, the biological significance of this interaction was assessed by ATPlite cell growth, clonogenic survival, and flow cytometry-based apoptosis assays. Results: DEPTOR promoted the proliferation and survival of ErbB2-positive breast cancer cells by directly interacting with and stabilizing ErbB2. Specifically, DEPTOR translocates to cell membrane and interacts with ErbB2 to disrupt ErbB2 polyubiquitination and degradation promoted by β-TrCP, an E3 ubiquitin ligase. DEPTOR knockdown destabilizes ErbB2 by shortening its protein half-life to inactivate ErbB2-PI3K-AKT-mTOR signaling, leading to the suppression of cell proliferation and survival by inducing apoptosis. Ectopic expression of a constitutively active ErbB2 mutant completely rescued the reduction in cell proliferation and survival by DEPTOR knockdown. Importantly, DEPTOR expression is increased in human breast cancer tissues and its overexpression correlates with poor patient survival. Moreover, DEPTOR is located on the cell membrane in ErbB2-positive breast cancer tissues, but not in tumor-adjacent normal tissues, indicating that DEPTOR may contribute to the oncogenic characteristics of ErbB2. Conclusions: Our study reveals a novel mechanism by which DEPTOR promotes breast cancer cell proliferation and survival by stabilizing ErbB2.
CAROTID PLAQUE TISSUE COMPOSITION IS RELATED TO INTRAPLAQUE NEOVASCULARIZATION IN PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Laura Mantella, Kayla N. Colledanchise, Marie-France Hetu, Julia Herr, Mitchell Wheatley, Steven Feinstein, Amer M. Johri
Journal: Journal of the American College of Cardiology (2021)
IMPROVED OUTCOMES OF SUPRAVENTRICULAR TACHYCARDIA ABLATIONS WITH THE USE OF THREE-DIMENSIONAL MAPPING
Authors: Stephanie Crass, Dario Manley-Casco, Justin Jevicks, MacKenzie Mayo, Lakshmi Saroja Gundapaneni, Komal Imtiaz, Dixy Rajkumar, Michael Battaglia, Timothy Shinn, Radmira Greenstein, Bipin Ravindran, Jihn Han, Edwin Zishiri, Shrinivas Hebsur
Journal: Journal of the American College of Cardiology (2021)
EFFICACY AND SAFETY OF INCLISIRAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POOLED ANALYSIS FROM THREE PHASE 3 CLINICAL TRIALS (ORION-9, -10 AND -11)
Authors: Ulf Landmesser, Kausik K. Ray, Frederick Raal, Lorena Garcia Conde, Mark Jaros, Wolfgang Koenig, Lawrence A. Leiter, Gregory G. Schwartz, David G. Kallend, R. Scott Wright
Journal: Journal of the American College of Cardiology (2021)
CHRONIC KIDNEY DISEASE AND MORTALITY IN UNCOMPLICATED VS COMPLICATED STEMI
Authors: Gautam R. Shroff, Christian Schmidt, Edward Tannenbaum, Roberto Pacheco, Timothy D. Smith, Ross Garberich, Scott Sharkey, Frank Aguirre, Mark Tannenbaum, Daniel Shivapour, Teresa Coulson, Timothy Henry, Santiago Garcia
Journal: Journal of the American College of Cardiology (2021)
ARTERIAL STIFFNESS AND LEFT VENTRICULAR GEOMETRY IN A MULTI-ETHNIC POPULATION
Authors: Francesca Calicchio, Afiachukwu Onuegbu, Song Shou Mao, April Kinninger, Ruby Havistin, Venkat Sanjay Manubolu, Ilana Golub, Lavanya Cherukuri, Divya Birudaraju, Khadije Ahmad, Vahid Rezvanizadeh, Ahmed Ghanem, Matthew Budoff
Journal: Journal of the American College of Cardiology (2021)
Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy
Authors: Laith Farah Al-Rabadi, Tiffany Caza, Claire Trivin-Avillach, Aylin R. Rodan, Nicole Andeen, Norifumi Hayashi, Brandi Williams, Monica P. Revelo, Fred Clayton, Jo Abraham, Edwin Lin, Willisa Liou, Chang-Jiang Zou, Nirupama Ramkumar, Tim Cummins, Daniel W. Wilkey, Issa Kawalit, Christian Herzog, Aaron Storey, Rick Edmondson, Ronald Sjoberg, Tianxin Yang, Jeremy Chien, Michael Merchant, John Arthur, Jon Klein, Chris Larsen, Laurence H. Beck
Journal: Journal of the American Society of Nephrology (2021)

Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%-20% of patients.A multipronged approach, using traditional and modern technologies, converged on a novel target antigen, and capitalized on the temporal variation in autoantibody titer for biomarker discovery. Immunoblotting of human glomerular proteins followed by differential immunoprecipitation and mass spectrometric analysis was complemented by laser-capture microdissection followed by mass spectrometry, elution of immune complexes from renal biopsy specimen tissue, and autoimmune profiling on a protein fragment microarray.These approaches identified serine protease HTRA1 as a novel podocyte antigen in a subset of patients with primary MN. Sera from two patients reacted by immunoblotting with a 51-kD protein within glomerular extract and with recombinant human HTRA1, under reducing and nonreducing conditions. Longitudinal serum samples from these patients seemed to correlate with clinical disease activity. As in PLA2R- and THSD7A- associated MN, anti-HTRA1 antibodies were predominantly IgG4, suggesting a primary etiology. Analysis of sera collected during active disease versus remission on protein fragment microarrays detected significantly higher titers of anti-HTRA1 antibody in active disease. HTRA1 was specifically detected within immune deposits of HTRA1-associated MN in 14 patients identified among three cohorts. Screening of 118 "quadruple-negative" (PLA2R-, THSD7A-, NELL1-, EXT2-negative) patients in a large repository of MN biopsy specimens revealed a prevalence of 4.2%.Conventional and more modern techniques converged to identify serine protease HTRA1 as a target antigen in MN.
Argon plasma coagulation of the papilla of Vater for treatment of a Dieulafoy lesion
Authors: Gianfranco Donatelli, Fabrizio Cereatti, Ilva Lodolo, Tullio Piardi
Journal: Endoscopy (2021)

A 54-year-old man was admitted to the emergency room for a syncope episode and melena. The laboratory test highlighted a hemoglobin of 6.8 g/dL, and 2 blood transfusions were performed. An upper endoscopy revealed stigmata of recent bleeding in the duodenum, and active bleeding was visualized at the level of the major papilla. Therefore, hemobilia or hemosuccus pancreaticus was suspected. An abdominal computed tomography (CT) scan did not reveal any underlying biliopancreatic disorder.
Variability and Costs of Low-Value Preoperative Testing for Cataract Surgery Within the Veterans Health Administration
Authors: Seshadri C. Mudumbai, Suzann Pershing, Tom Bowe, Robin N. Kamal, Erika D. Sears, Mary T. Hawn, Dan Eisenberg, Andrea K. Finlay, Hildi Hagedorn, Alex H. S. Harris
Journal: JAMA Network Open (2021)

The Choosing Wisely guidelines indicate that preoperative testing is often unnecessary and wasteful for patients undergoing cataract operations. However, little is known about the impact of these widely disseminated guidelines within the US Veterans Health Administration (VHA) system.To examine the extent, variability, associated factors, and costs of low-value tests (LVTs) prior to cataract operations in the VHA.This cohort study examined records of all patients receiving cataract operations within the VHA in fiscal year 2017 (October 1, 2016, to September 31, 2017). Records from 135 facilities nationwide supporting both ambulatory and inpatient surgery were included.A laboratory test occurring within 30 days prior to cataract surgery and within 30 days after clinic evaluation.Overall national and facility-level rates and associated costs of receiving any of 8 common LVTs in the 30 days prior to cataract surgery. The patient characteristics, procedure type, and facility-level factors associated with receiving at least 1 test, the number of tests received, and receipt of a bundle of 4 tests (complete blood count, basic metabolic profile, chest radiograph, and electrocardiogram).A total of 69 070 cataract procedures were identified among 50 106 patients (66 282 [96.0%] men; mean [SD] age, 71.7 [8.1] years; 53 837 [77.9%] White, 10 292 [14.9%] Black). Most of the patient population had either overweight (23 292 [33.7%] patients) or obesity (27 799 [40.2%] patients). Approximately 49% of surgical procedures (33 424 procedures) were preceded by 1 or more LVT with an overall LVT cost of $2 597 623. Among patients receiving LVTs, electrocardiography (7434 patients [29.9%]) was the most common, with some patients also receiving more costly tests, including chest radiographs (489 patients [8.2%]) and pulmonary function tests (127 patients [3.4%]). For receipt of any LVT, the intraclass correlation coefficient was 0.61 (P < .001) at the facility level and 0.06 (P < .001) at the surgeon level, indicating the substantial contribution of the facility to amount of tests given.Despite existing guidelines, use of LVTs prior to cataract surgery is both common and costly within a large, national integrated health care system. Our results suggest that publishing evidence-based guidelines alone-such as the Choosing Wisely campaign-may not sufficiently influence individual physician behavior, and that system-level efforts to directly deimplement LVTs may therefore necessary to effect sustained change.
PREVALENCE OF CARDIAC ARRHYTHMIAS IN HEART FAILURE PATIENTS WITH AND WITHOUT HYPOCALCEMIA: A NATIONAL INPATIENT SAMPLE ANALYSIS
Authors: Ramtej Atluri, Mukunthan Murthi, Sujitha Velagapudi, Genaro Velazquez, Hafeez Shaka, Mouna Kodali
Journal: Journal of the American College of Cardiology (2021)